Clinical Trial Update: A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating cemiplimab, a PD-1 inhibitor, for high-risk localized, locally recurrent, or regionally advanced skin squamous cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Squamous Cell Carcinoma

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)

Snippet

Sponsor: University of Southern California | Conditions: Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING